Atossa Therapeutics, Inc.

NasdaqCM:ATOS Stock Report

Market Cap: US$20.3m

Atossa Therapeutics Future Growth

Future criteria checks 3/6

Atossa Therapeutics is forecast to grow earnings and revenue by 58.3% and 58.4% per annum respectively while EPS is expected to grow by 59.2% per annum.

Key information

58.3%

Earnings growth rate

59.23%

EPS growth rate

Biotechs earnings growth25.3%
Revenue growth rate58.4%
Future return on equityn/a
Analyst coverage

Low

Last updated01 Jul 2026

Recent future growth updates

Recent updates

Analysis Article • Dec 03

Is Atossa Therapeutics (NASDAQ:ATOS) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Jul 15

Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Apr 01

Here's Why We're Not Too Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Nov 12

We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Nov 08

Atossa Therapeutics: Important News, But The Company Still Has A Long Way To Go

Summary Atossa Therapeutics focuses on developing endoxifen for hormone receptor-positive breast cancer, with promising early-stage trial results but lacks definitive proof of efficacy. The company has strong financials, with $79.5 million in cash and a cash runway of 13-14 quarters, minimizing immediate dilution risk. Despite promising signals, preventive endocrine therapy faces heavy clinical resistance and requires well-powered confirmatory studies to prove its viability. Given the high risk, I maintain a "Sell" rating, anticipating better entry points in the future. Read the full article on Seeking Alpha
Analysis Article • Jul 01

We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Mar 07

Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Nov 08

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Apr 26

Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Jan 09

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Earnings and Revenue Growth Forecasts

NasdaqCM:ATOS - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202811948N/AN/A2
12/31/2027N/A-39N/A-363
12/31/2026N/A-37N/A-363
3/31/2026N/A-38-33-33N/A
12/31/2025N/A-35-30-30N/A
9/30/2025N/A-30-26-26N/A
6/30/2025N/A-29-25-25N/A
3/31/2025N/A-26-22-22N/A
12/31/2024N/A-26-21-21N/A
9/30/2024N/A-27-20-20N/A
6/30/2024N/A-26-19-19N/A
3/31/2024N/A-30-19-19N/A
12/31/2023N/A-30-21-21N/A
9/30/2023N/A-30-20-20N/A
6/30/2023N/A-32-21-21N/A
3/31/2023N/A-28-23-23N/A
12/31/2022N/A-27-21-21N/A
9/30/2022N/A-24-20-20N/A
6/30/2022N/A-21-18-18N/A
3/31/2022N/A-22-17-17N/A
12/31/2021N/A-21-16-16N/A
9/30/2021N/A-28-16-16N/A
6/30/2021N/A-26-16-16N/A
3/31/2021N/A-23-13-13N/A
12/31/2020N/A-22-12-12N/A
9/30/2020N/A-13-11-11N/A
6/30/2020N/A-13-10-10N/A
3/31/2020N/A-16-10-10N/A
12/31/2019N/A-17N/A-9N/A
9/30/2019N/A-17N/A-9N/A
6/30/2019N/A-17N/A-9N/A
3/31/2019N/A-25N/A-9N/A
12/31/2018N/A-23N/A-9N/A
9/30/2018N/A-23N/A-8N/A
6/30/2018N/A-22N/A-8N/A
3/31/2018N/A-11N/A-7N/A
12/31/2017N/A-11N/A-7N/A
9/30/2017N/A-11N/A-6N/A
6/30/2017N/A-9N/A-4N/A
3/31/2017N/A-6N/A-4N/A
12/31/2016N/A-6N/A-5N/A
9/30/20160-6N/A-8N/A
6/30/20160-10N/A-12N/A
3/31/20160-12N/A-14N/A
12/31/20150-13N/A-14N/A
9/30/20150-13N/A-13N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ATOS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.5%).

Earnings vs Market: ATOS is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ATOS is expected to become profitable in the next 3 years.

Revenue vs Market: ATOS is forecast to have no revenue next year.

High Growth Revenue: ATOS is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ATOS's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/10 20:06
End of Day Share Price 2026/07/10 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Atossa Therapeutics, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward WooAscendiant Capital Markets LLC
Pooya HemamiEdison Investment Research
Jason McCarthyMaxim Group